Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bardoxolone Methyl PK Study with Itraconazole in Healthy Volunteers
NCT03264079Phase 1Completed
- Sponsor
- Biogen
- Start
- Oct 2017
- Primary completion
- Nov 2017
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bardoxolone methyl in chronic kidney disease (CKD), sponsored by Biogen. Primary endpoints: Area under the plasma concentration-time curve from time 0 to the last measurable time point at 28 days, Area under the plasma concentration-time curve extrapolated to infinity at 28 days and 1 more. Started Oct 2017; status: completed.
02
Drugs
bardoxolone methyl
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03264079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03264079.